Discovery Life Sciences operates a biospecimen and biomarker platform serving biopharma, diagnostics, and academic research. The tech stack is operationally focused—LIMS (Labware), Salesforce, NetSuite, lab equipment (Leica)—with no AI/ML or modern data tooling visible, yet the hiring mix shows emerging data (2 roles) and engineering (1 role) alongside a research-heavy org (11 roles). Active projects center on LIMS implementation, regulatory compliance, and process harmonization, while pain points cluster around system validation, data transfer delays, and operational efficiency—classic signals of a scaling biotech services business managing high sample volume and regulatory complexity across multiple lab sites.
Discovery Life Sciences is a biospecimen and biomarker provider based in Huntsville, Alabama, founded in 2018. The company sources, characterizes, and analyzes human biological materials—including primary cells, blood products, and cancer tissues—for cell and gene therapy, precision medicine, and diagnostic research. They operate across both Research Use Only (RUO) and clinical-grade (GMP) materials, managing hundreds of concurrent studies and thousands of biospecimens in parallel. The business model combines supply (donor pools, cryopreserved materials) with analytical services (multi-omic testing, biomarker assays), positioning them as an integrated vendor to reduce customer friction from managing multiple third parties. Operations span the United States, Germany, Bulgaria, and Poland.
Labware LIMS, Salesforce, NetSuite, Leica lab equipment, Microsoft Office, Google Workspace, and Smartsheet. No modern data or analytics platforms in use.
Headquartered in Huntsville, Alabama. Active hiring and operations in the United States, Germany, Bulgaria, and Poland.
Other companies in the same industry, closest in size